Scheltens P, De Strooper B, Kivipelto M, Holstege H, Chetelat G, Teunissen CE, et al. Alzheimer’s disease. Lancet. 2021;397(10284):1577–90.

Article  CAS  PubMed  PubMed Central  Google Scholar 

As A. 2021 Alzheimer’s disease facts and figures. Alzheimers Dementia. 2021;17(3):327–406.

Article  Google Scholar 

Leng FD, Edison P. Neuroinflammation and microglial activation in Alzheimer disease: where do we go from here? Nat Rev Neurol. 2021;17(3):157–72.

Article  PubMed  Google Scholar 

Lane CA, Hardy J, Schott JM. Alzheimer’s disease. Eur J Neurol. 2018;25(1):59–70.

Article  CAS  PubMed  Google Scholar 

Long JM, Holtzman DM. Alzheimer disease: an update on pathobiology and treatment strategies. Cell. 2019;179(2):312–39.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jeremic D, Navarro-Lopez JD, Jimenez-Diaz L. Efficacy and Safety of anti-amyloid-beta monoclonal antibodies in current Alzheimer’s disease phase III clinical trials: a systematic review and interactive web app-based meta-analysiS. Ageing Res Rev. 2023;90:102012.

Article  CAS  PubMed  Google Scholar 

Cuello AC. Early and Late CNS Inflammation in Alzheimer’s Disease: Two Extremes of a Continuum? Trends Pharmacol Sci. 2017;38(11):956–66.

Article  CAS  PubMed  Google Scholar 

Gratuze M, Leyns CEG, Holtzman DM. New insights into the role of TREM2 in Alzheimer’s disease. Mol Neurodegener. 2018;13(1):66.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Guerreiro R, Wojtas A, Bras J, Carrasquillo M, Rogaeva E, Majounie E, et al. TREM2 Variants in Alzheimer’s disease. N Engl J Med. 2013;368(2):117–27.

Article  CAS  PubMed  Google Scholar 

Craig-Schapiro R, Perrin RJ, Roe CM, Xiong C, Carter D, Cairns NJ, et al. YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer’s disease. Biol Psychiatry. 2010;68(10):903–12.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bonneh-Barkay D, Wang G, Starkey A, Hamilton RL, Wiley CA. In vivo CHI3L1 (YKL-40) expression in astrocytes in acute and chronic neurological diseases. J Neuroinflammation. 2010;7:34.

Article  PubMed  PubMed Central  Google Scholar 

Querol-Vilaseca M, Colom-Cadena M, Pegueroles J, San Martin-Paniello C, Clarimon J, Belbin O, et al. YKL-40 (Chitinase 3-like I) is expressed in a subset of astrocytes in Alzheimer’s disease and other tauopathies. J Neuroinflammation. 2017;14(1):118.

Article  PubMed  PubMed Central  Google Scholar 

Bhardwaj R, Yester JW, Singh SK, Biswas DD, Surace MJ, Waters MR, et al. RelB/p50 complexes regulate cytokine-induced YKL-40 expression. J Immunol. 2015;194(6):2862–70.

Article  CAS  PubMed  Google Scholar 

Connolly K, Lehoux M, O’Rourke R, Assetta B, Erdemir GA, Elias JA, et al. Potential role of chitinase-3-like protein 1 (CHI3L1/YKL-40) in neurodegeneration and Alzheimer’s disease. Alzheimers Dement. 2023;19(1):9–24.

Article  CAS  PubMed  Google Scholar 

Colton CA, Mott RT, Sharpe H, Xu Q, Van Nostrand WE, Vitek MP. Expression profiles for macrophage alternative activation genes in AD and in mouse models of AD. J Neuroinflamm. 2006;3:27.

Article  Google Scholar 

Moreno-Rodriguez M, Perez SE, Nadeem M, Malek-Ahmadi M, Mufson EJ. Frontal cortex chitinase and pentraxin neuroinflammatory alterations during the progression of Alzheimer’s disease. J Neuroinflamm. 2020;17(1):58.

Article  CAS  Google Scholar 

Lananna BV, McKee CA, King MW, Del-Aguila JL, Dimitry JM, Farias FHG, et al. Chi3l1/YKL-40 is controlled by the astrocyte circadian clock and regulates neuroinflammation and Alzheimer’s disease pathogenesis. Sci Transl Med. 2020;12(574):eaax3519.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Deane R, Bell RD, Sagare A, Zlokovic BV. Clearance of amyloid-beta peptide across the blood-brain barrier: implication for therapies in Alzheimer’s disease. CNS Neurol Disord Drug Targets. 2009;8(1):16–30.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang Y, Cella M, Mallinson K, Ulrich JD, Young KL, Robinette ML, et al. TREM2 lipid sensing sustains the microglial response in an Alzheimer’s disease model. Cell. 2015;160(6):1061–71.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Brandenburg LO, Konrad M, Wruck CJ, Koch T, Lucius R, Pufe T. Functional and physical interactions between formyl-peptide-receptors and scavenger receptor MARCO and their involvement in amyloid beta 1–42-induced signal transduction in glial cells. J Neurochem. 2010;113(3):749–60.

Article  CAS  PubMed  Google Scholar 

Slowik A, Merres J, Elfgen A, Jansen S, Mohr F, Wruck CJ, et al. Involvement of formyl peptide receptors in receptor for advanced glycation end products (RAGE)–and amyloid beta 1–42-induced signal transduction in glial cells. Mol Neurodegener. 2012;7:55.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fukami S, Watanabe K, Iwata N, Haraoka J, Lu B, Gerard NP, et al. Abeta-degrading endopeptidase, neprilysin, in mouse brain: synaptic and axonal localization inversely correlating with Abeta pathology. Neurosci Res. 2002;43(1):39–56.

Article  CAS  PubMed  Google Scholar 

Halle A, Hornung V, Petzold GC, Stewart CR, Monks BG, Reinheckel T, et al. The NALP3 inflammasome is involved in the innate immune response to amyloid-beta. Nat Immunol. 2008;9(8):857–65.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Abraham CR. Reactive astrocytes and alpha1-antichymotrypsin in Alzheimer’s disease. Neurobiol Aging. 2001;22(6):931–6.

Article  CAS  PubMed  Google Scholar 

Pomilio C, Pavia P, Gorojod RM, Vinuesa A, Alaimo A, Galvan V, et al. Glial alterations from early to late stages in a model of Alzheimer’s disease: Evidence of autophagy involvement in Abeta internalization. Hippocampus. 2016;26(2):194–210.

Article  CAS  PubMed  Google Scholar 

Morris AW, Carare RO, Schreiber S, Hawkes CA. The cerebrovascular basement membrane: role in the clearance of beta-amyloid and cerebral amyloid angiopathy. Front Aging Neurosci. 2014;6:251.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, et al. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature. 2002;416(6880):535–9.

Article  CAS  PubMed  Google Scholar 

Oakley H, Cole SL, Logan S, Maus E, Shao P, Craft J, et al. Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer’s disease mutations: potential factors in amyloid plaque formation. J Neurosci. 2006;26(40):10129–40.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Le Douce J, Maugard M, Veran J, Matos M, Jego P, Vigneron PA, et al. Impairment of glycolysis-derived l-serine production in astrocytes contributes to cognitive deficits in Alzheimer’s disease. Cell Metab. 2020;31(3):503-17 e8.

Article  PubMed  Google Scholar 

Elder GA, Sosa MAG, De Gasperi R. Transgenic mouse models of Alzheimer’s disease. Mt Sinai J Med. 2010;77(1):69–81.

Article  PubMed  PubMed Central  Google Scholar 

Hall AM, Roberson ED. Mouse models of Alzheimer’s disease. Brain Res Bull. 2012;88(1):3–12.

Article  CAS  PubMed  Google Scholar 

Jullienne A, Trinh MV, Obenaus A. Neuroimaging of mouse models of Alzheimer’s disease. Biomedicines. 2022. https://doi.org/10.3390/biomedicines10020305.

Article  PubMed  PubMed Central  Google Scholar 

Knafo S, Sanchez-Puelles C, Palomer E, Delgado I, Draffin JE, Mingo J, et al. PTEN recruitment controls synaptic and cognitive function in Alzheimer’s models. Nat Neurosci. 2016;19(3):443–53.

Article  CAS  PubMed  Google Scholar 

Wang YB, Wong CW, Yan MF, Li LS, Liu T, Or PMY, et al. Differential regulation of the pro-inflammatory biomarker, YKL-40/CHI3L1, by PTEN/phosphoinositide 3-kinase and JAK2/STAT3 pathways in glioblastoma. Cancer Lett. 2018;429:54–65.

Article  CAS  PubMed  Google Scholar 

Srinivasan R, Lu TY, Chai H, Xu J, Huang BS, Golshani P, et al. New transgenic mouse lines for selectively targeting astrocytes and studying calcium signals in astrocyte processes In Situ and In Vivo. Neuron. 2016;92(6):1181–95.

Article  CAS  PubMed  PubMed Central